Accession Number: | 0000914190-20-000182 |
Date: | 2020-05-21 |
Issuer: | BIO-TECHNE CORP (TECH) |
Original Submission Date: |
BAUMGARTNER ROBERT V
5775 WAYZATA BOULEVARD, SUITE 400
MINNEAPOLIS, MN 55416
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-05-21 | M | 5,000 | a | $70.35 | 14,221 | direct | ||
COMMON STOCK | 2020-05-21 | S | 1,300 | d | $265.35 | 12,921 | direct | ||
COMMON STOCK | 2020-05-21 | S | 1,601 | d | $266.07 | 11,320 | direct | ||
COMMON STOCK | 2020-05-21 | S | 1,974 | d | $267.32 | 9,346 | direct | ||
COMMON STOCK | 2020-05-21 | S | 125 | d | $267.94 | 9,221 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTIONS (RIGHT TO BUY) | 70.35 | 2020-05-21 | deemed execution date | M | 5,000 (d) | 2011-10-27 | 2021-10-26 | common stock 5,000 | $70.35 | 0 | direct | |
STOCK OPTIONS (RIGHT TO BUY) | 66.9 | 2020-05-21 | deemed execution date | 0 ( ) | 2012-10-25 | 2022-10-24 | common stock 5,000 | $66.90 | 5,000 | direct | ||
STOCK OPTIONS (RIGHT TO BUY) | 87.39 | 2020-05-21 | deemed execution date | 0 ( ) | 2013-10-31 | 2023-10-30 | common stock 4,000 | $87.39 | 4,000 | direct | ||
STOCK OPTIONS (RIGHT TO BUY) | 91.78 | 2020-05-21 | deemed execution date | 0 ( ) | 2014-10-30 | 2024-10-30 | common stock 4,000 | $91.78 | 4,000 | direct | ||
STOCK OPTIONS (RIGHT TO BUY) | 87.34 | 2020-05-21 | deemed execution date | 0 ( ) | 2016-10-29 | 2025-10-28 | common stock 4,260 | $87.34 | 4,260 | direct | ||
STOCK OPTIONS (RIGHT TO BUY) | 101.19 | 2020-05-21 | deemed execution date | 0 ( ) | 2017-10-26 | 2026-10-26 | common stock 3,985 | $101.19 | 3,985 | direct | ||
STOCK OPTIONS (RIGHT TO BUY) | 125.05 | 2020-05-21 | deemed execution date | 0 ( ) | 2018-10-25 | 2027-10-26 | common stock 3,125 | $125.05 | 3,125 | direct | ||
STOCK OPTIONS (RIGHT TO BUY) | 179.84 | 2020-05-21 | deemed execution date | 0 ( ) | 2019-10-24 | 2028-10-25 | common stock 1,898 | $179.84 | 1,898 | direct | ||
STOCK OPTIONS (RIGHT TO BUY) | 201.64 | 2020-05-21 | deemed execution date | 0 ( ) | 2029-10-24 | common stock 2,011 | $201.64 | 2,011 | direct |
ID | footnote |
---|---|
f1 | the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $264.64 to $265.6276, inclusive. the reporting person undertakes to provide bio-techne corporation, any security holder of bio-techne corporation, or the staff of the securities and exchange commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
f2 | the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $265.68 to $266.6712, inclusive. the reporting person undertakes to provide bio-techne corporation, any security holder of bio-techne corporation, or the staff of the securities and exchange commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
f3 | the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $266.82 to $267.80, inclusive. the reporting person undertakes to provide bio-techne corporation, any security holder of bio-techne corporation, or the staff of the securities and exchange commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
f4 | the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $267.82 to $267.97, inclusive. the reporting person undertakes to provide bio-techne corporation, any security holder of bio-techne corporation, or the staff of the securities and exchange commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
f5 | the option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of bio-techne's 2020 annual meeting of shareholders. |